These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 29562730)

  • 21. Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation.
    Li B; Yu S
    Biol Pharm Bull; 2003 Jun; 26(6):780-6. PubMed ID: 12808286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fast and long acting neoflavonoids dalbergin isolated from Dalbergia sissoo heartwood is osteoprotective in ovariectomized model of osteoporosis: Osteoprotective effect of Dalbergin.
    Choudhary D; Kushwaha P; Gautam J; Kumar P; Verma A; Kumar A; Maurya SW; Siddiqui IR; Mishra PR; Maurya R; Trivedi R
    Biomed Pharmacother; 2016 Oct; 83():942-957. PubMed ID: 27522257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
    Kim JY; Cheon YH; Oh HM; Rho MC; Erkhembaatar M; Kim MS; Lee CH; Kim JJ; Choi MK; Yoon KH; Lee MS; Oh J
    Bone; 2014 Mar; 60():104-11. PubMed ID: 24361669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
    Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
    Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors.
    Strålberg F; Kassem A; Kasprzykowski F; Abrahamson M; Grubb A; Lindholm C; Lerner UH
    J Leukoc Biol; 2017 May; 101(5):1233-1243. PubMed ID: 28196851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DUSP6 expression is associated with osteoporosis through the regulation of osteoclast differentiation via ERK2/Smad2 signaling.
    Zhang B; Yuan P; Xu G; Chen Z; Li Z; Ye H; Wang J; Shi P; Sun X
    Cell Death Dis; 2021 Sep; 12(9):825. PubMed ID: 34475393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
    Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
    Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
    Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
    Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gymnasterkoreayne F inhibits osteoclast formation by suppressing NFATc1 and DC-STAMP expression.
    Kim HJ; Hong J; Jung JW; Kim TH; Kim JA; Kim YH; Kim SY
    Int Immunopharmacol; 2010 Nov; 10(11):1440-7. PubMed ID: 20831919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
    Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
    Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical role of beta3 integrin in experimental postmenopausal osteoporosis.
    Zhao H; Kitaura H; Sands MS; Ross FP; Teitelbaum SL; Novack DV
    J Bone Miner Res; 2005 Dec; 20(12):2116-23. PubMed ID: 16294265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between fluoride exposure and osteoclast markers during RANKL-induced osteoclast differentiation.
    Junrui P; Bingyun L; Yanhui G; Xu J; Darko GM; Dianjun S
    Environ Toxicol Pharmacol; 2016 Sep; 46():241-245. PubMed ID: 27500448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Li L; Sapkota M; Kim SW; Soh Y
    Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant receptor activator of nuclear factor κB exhibits more marked inhibitory effects on osteoclasts compared with recombinant osteoprotegerin in vitro and in vivo.
    Xiong Q; Xin L; Zhang L; Tang P; Zhang L
    Mol Med Rep; 2015 Jul; 12(1):631-8. PubMed ID: 25738879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative proteomic and metabolomic analysis reveal the antiosteoporotic molecular mechanism of icariin from Epimedium brevicornu maxim.
    Xue L; Jiang Y; Han T; Zhang N; Qin L; Xin H; Zhang Q
    J Ethnopharmacol; 2016 Nov; 192():370-381. PubMed ID: 27422162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption.
    Mizoguchi F; Izu Y; Hayata T; Hemmi H; Nakashima K; Nakamura T; Kato S; Miyasaka N; Ezura Y; Noda M
    J Cell Biochem; 2010 Apr; 109(5):866-75. PubMed ID: 20039311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lycopene treatment against loss of bone mass, microarchitecture and strength in relation to regulatory mechanisms in a postmenopausal osteoporosis model.
    Ardawi MM; Badawoud MH; Hassan SM; Rouzi AA; Ardawi JMS; AlNosani NM; Qari MH; Mousa SA
    Bone; 2016 Feb; 83():127-140. PubMed ID: 26549245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiosteoclastic activity of milk thistle extract after ovariectomy to suppress estrogen deficiency-induced osteoporosis.
    Kim JL; Kim YH; Kang MK; Gong JH; Han SJ; Kang YH
    Biomed Res Int; 2013; 2013():919374. PubMed ID: 23781510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.